Skip to main content
SpringerLink
Log in
Book cover

Platinum and Other Heavy Metal Compounds in Cancer Chemotherapy

Molecular Mechanisms and Clinical Applications

  • Book
  • © 2009

Overview

Editors:
  1. Andrea Bonetti

    1. Department of Oncology, Mater Salutis Hospital, Legnago, Italy

    View editor publications

    You can also search for this editor in PubMed   Google Scholar

  2. Roberto Leone

    1. Institute of Pharmacology, University of Verona, Verona, Italy

    View editor publications

    You can also search for this editor in PubMed   Google Scholar

  3. Franco M. Muggia

    1. Division of Medical Oncology, New York University School of Medicine and the NYU Cancer Institute, New York, USA

    View editor publications

    You can also search for this editor in PubMed   Google Scholar

  4. Stephen B. Howell

    1. Department of Medicine and the Moores Cancer Center, University of California, San Diego, USA

    View editor publications

    You can also search for this editor in PubMed   Google Scholar

  • The papers in this volume have been presented at the X International Symposium on Platinum Coordination Compounds in Cancer Chemotherapy held in Verona, Italy, from November 30th to December 3rd 2007.
  • http://www.ispcc2007.org/scientific.htm

Part of the book series: Cancer Drug Discovery and Development (CDD&D)

This is a preview of subscription content, log in via an institution to check access.

Access this book

Log in via an institution
eBook USD 169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book USD 219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Other ways to access

Licence this eBook for your library

Institutional subscriptions

Table of contents (42 chapters)

  1. DNA Damage and Signal Transduction: Recognition/Repair And Cell-Response

    1. Differences in Conformation and Conformational Dynamics Between Cisplatin and Oxaliplatin DNA Adducts

      • Stephen G. Chaney, Srinivas Ramachandran, Shantanu Sharma, Nikolay V. Dokholyan, Brenda Temple, Debadeep Bhattacharyya et al.
      Pages 157-169

    2. Regrowth Resistance: Low-Level Platinum Resistance Mediated by Rapid Recovery from Platinum-Induced Cell-Cycle Arrest

      • Britta Stordal, Ross Davey
      Pages 171-176

    3. Targeting Nucleotide Excision Repair as a Mechanism to Increase Cisplatin Efficacy

      • John J. Turchi, Sarah C. Shuck, Emily A. Short, Brooke J. Andrews
      Pages 177-187

    4. CHK2 and ERCC1 in the DNA Adduct Repair Pathway that Mediates Acquired Cisplatin Resistance

      • Jing Jie Yu, Xiaobing Liang, Qing-Wu Yan, Eddie Reed, Antonio Tito Fojo, Ying Guo et al.
      Pages 189-194

    5. Modulation of Survival Pathways in Ovarian Carcinoma Cells Resistant to Platinum Compounds

      • Paola Perego, Valentina Benedetti, Cinzia Lanzi, Franco Zunino
      Pages 195-200

    6. Paraptotic Cell Death Induced by the Thioxotriazole Copper Complex A0: A New Tool to Kill Apoptosis-Resistant Cancer Cells

      • Saverio Tardito, Claudio Isella, Enzo Medico, Luciano Marchiò, Maurizio Lanfranchi, Ovidio Bussolati et al.
      Pages 201-207

  2. Clinical Applications

    1. Platinum Compounds and Radiation

      • Lea Baer, Franco M. Muggia, Silvia C. Formenti
      Pages 211-223

    2. Treating Cisplatin-Resistant Cancer: A Systematic Analysis of Oxaliplatin or Paclitaxel Salvage Chemotherapy

      • Britta Stordal, Nick Pavlakis, Ross Davey
      Pages 225-230

    3. Platinum Compounds in Lung Cancer: Current Status

      • Kevin Tay, Martin Gutierrez, Giuseppe Giaccone
      Pages 231-242

    4. Is Lipoplatinum Monotherapy an Active Alternative in Second Line Treatment of Metastatic Non–Small Cell Lung Cancer? A Phase II Trial

      • Alberto Ravaioli, Manuela Fantini, Fabrizio Drudi, Maximilian Papi, Enzo Pasquini, Maurizio Marangolo et al.
      Pages 243-249

    5. Combining Platinums in Gastric Cancer

      • Florian Lordick, Dirk Jäger
      Pages 251-270

    6. Oxaliplatin-Based Chemotherapy for Colon Cancer

      • Andrea Bonetti, Furini Lara
      Pages 271-284

    7. First-Line Systemic Chemotherapy with Folfoxiri Followed by Radical Surgical Resection of Metastases for the Treatment of Unresectable Metastatic Colorectal Cancer Patients

      • Enrico Vasile, Gianluca Masi, Fotios Loupakis, Samanta Cupini, Giacomo Giulio Baldi, Lorenzo Fornaro et al.
      Pages 285-293

    8. Pre-operative Radio-Chemotherapy of Rectal Cancer: Toxicity and Preliminary Results with the Addition of Weekly Oxaliplatin

      • Francesco Dionisi, Daniela Musio, Gian Paolo Spinelli, Giuseppe Parisi, Nicola Raffetto, Enzo Banelli et al.
      Pages 295-306

    9. The Role of Platins in Newly Diagnosed Endometrial Cancer

      • Paul J. Hoskins
      Pages 307-315

    10. Platinum Compounds: Key Ingredients in Ovarian Cancer Treatment and Strategies

      • Franco M. Muggia
      Pages 317-328

    11. Intraperitoneal Chemotherapy: An Important Strategy in Ovarian Cancer Treatment

      • Franco M. Muggia
      Pages 329-333

    12. Novel Strategies for Enhancing the Efficacy of Intraperitoneal Chemotherapy for Patients with Ovarian Cancer

      • Stephen B. Howell
      Pages 335-341

    13. Laparoscopically Assisted Heated Intra-Operative Intraperitoneal Chemotherapy (HIPEC): Technical Aspect and Pharmacokinetics Data

      • Gwenaël Ferron, Amélie Gesson-Paute, Laurence Gladieff, Fabienne Thomas, Etienne Chatelut, Denis Querleu
      Pages 343-351

    14. Organic Cation Transporters 2 as Mediators of Cisplatin Nephrotoxicity

      • Giuliano Ciarimboli
      Pages 353-358
Back to top

Keywords

About this book

Cisplatin, the first member of the family of platinum-containing chemotherapeutic agents, was discovered by Barnett Rosenberg in 1965 and approved by the FDA for marketing in 1978. After 30 years of use in the clinic, cisplatin remains a central element of many treatment regimens. Cisplatin is still an irreplaceable component of a regimen that produces high cure rates in even advanced nonseminomatous germ-cell cancers, and is widely used in the treatment of ovarian cancers and other gynecologic cancers, head and neck, and numerous other tumor types. The development of carboplatin has reduced some of the adverse events associated with cisplatin treatment, and the introduction of the DACH platinum compound oxaliplatin has broadened the spectrum of activity of the platinums to include gastro-intestinal cancers, especially colorectal cancer. The clinical importance of this family of drugs continues to drive investigation into how these drugs work and how to improve their efficacy and reduce their toxicity. The papers in this volume were presented in Verona, Italy, during the tenth International Symposium on Platinum Coordination Compounds in Cancer Chemotherapy. The symposium was jointly organized by the Department of Oncology of the Mater Salutis Hospital – Azienda Sanitaria Locale 21 of the Veneto Region – and by the Department of Medicine and Public Health, Section of Pharmacology, the University of Verona. They reflect the vitality of this field and the increasing use of new molecular and cell biologic, genetic, and biochemical tools to identify approaches to further improve their use.

Editors and Affiliations

  • Department of Oncology, Mater Salutis Hospital, Legnago, Italy

    Andrea Bonetti

  • Institute of Pharmacology, University of Verona, Verona, Italy

    Roberto Leone

  • Division of Medical Oncology, New York University School of Medicine and the NYU Cancer Institute, New York, USA

    Franco M. Muggia

  • Department of Medicine and the Moores Cancer Center, University of California, San Diego, USA

    Stephen B. Howell

Bibliographic Information

Publish with us

Policies and ethics

Back to top

Search

Navigation